Precision Biosciences stock holds its Nasdaq listing
Published on 09/23/2026 at 01:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Precision Biosciences stock remains listed on Nasdaq under the ticker DTIL as of September 22, 2026. Precision Biosciences develops gene editing products, with its platform focused on targeted DNA modification for therapeutic and research applications.
Nasdaq identity remains intact
The company is identified by ISIN US74019P1084 and trades in US dollars on Nasdaq. Its primary listing and ticker provide the relevant reference point for investors monitoring DTIL rather than secondary quotations.
Gene editing remains the core
Precision Biosciences uses its ARCUS gene editing platform in programs designed to modify specific DNA sequences. The company operates in biotechnology, where clinical progress, financing capacity and regulatory milestones can have a material effect on valuation.
DTIL remains a biotechnology listing
DTIL stock is associated with Precision Biosciences and the Nasdaq biotechnology universe as of September 22, 2026. The trading venue, ticker and ISIN establish the security identity used for this article.
Precision Biosciences stock data
- Company: Precision Biosciences, Inc.
- ISIN: US74019P1084
- Ticker: DTIL
- Trading venue: Nasdaq
- Sector / Industry: Health Care / Biotechnology
